Return To Growth In Biosimilars A Priority For Biogen

Full-Year Biosimilars Revenue Expected To Be Down Versus 2021

 
• By Chloe Kent
  
Growth man drawing graph pen
Biogen has listed biosimilars growth as one of its priorities. • Source: Christian Horz / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business